Can a cheap drug make ear surgery safer and faster?
NCT ID NCT06434636
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether a low dose of tranexamic acid, a drug that helps blood clot, could reduce bleeding during middle ear surgery. 100 adults undergoing microscopic or endoscopic ear surgery received either the drug or a placebo. The goal was to see if the drug improved the surgeon's view and satisfaction by limiting bleeding, which could shorten surgery time and reduce complications.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tranexamic acid
- What this could lead to
- If effective, this could offer a simple way to reduce bleeding during ear surgery, potentially shortening operation times and improving surgical outcomes.
- What could go wrong
- This is a small, completed trial with 100 participants, so results may not apply to all patients. Tranexamic acid can rarely cause blood clots or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Individuals between the ages of 18-65 * Individuals with ASA I (no additional disease) or ASA II (mild systemic disease) * Those who do not have a disease such as thrombophilia or bleeding diathesis will be included in the study Exclusion Criteria: * Patients with ASA III (those with uncontrolled chronic disease) or above * Patients with cardiovascular disease, congestive heart failure, coronary artery disease, cerebrovascular insufficiency, renal or hepatic failure * Patients with thrombophilia, bleeding diathesis, coagulation defects * Pregnant patients * Those with a history of any allergic reaction to tranexamic acid and its derivatives will be excluded from the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Middle ear disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erciyes Üniversitesi
Kayseri, Talas, 38000, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.